全文获取类型
收费全文 | 281篇 |
免费 | 48篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 7篇 |
基础医学 | 87篇 |
口腔科学 | 1篇 |
临床医学 | 14篇 |
内科学 | 67篇 |
皮肤病学 | 2篇 |
神经病学 | 64篇 |
特种医学 | 2篇 |
外科学 | 34篇 |
综合类 | 1篇 |
预防医学 | 10篇 |
眼科学 | 5篇 |
药学 | 9篇 |
中国医学 | 1篇 |
肿瘤学 | 22篇 |
出版年
2023年 | 5篇 |
2022年 | 2篇 |
2021年 | 15篇 |
2020年 | 4篇 |
2019年 | 9篇 |
2018年 | 24篇 |
2017年 | 13篇 |
2016年 | 15篇 |
2015年 | 16篇 |
2014年 | 32篇 |
2013年 | 29篇 |
2012年 | 29篇 |
2011年 | 19篇 |
2010年 | 8篇 |
2009年 | 5篇 |
2008年 | 12篇 |
2007年 | 13篇 |
2006年 | 7篇 |
2005年 | 10篇 |
2004年 | 9篇 |
2003年 | 13篇 |
2002年 | 7篇 |
2001年 | 2篇 |
2000年 | 5篇 |
1999年 | 4篇 |
1998年 | 2篇 |
1997年 | 1篇 |
1996年 | 2篇 |
1995年 | 4篇 |
1993年 | 1篇 |
1992年 | 3篇 |
1991年 | 1篇 |
1989年 | 1篇 |
1988年 | 2篇 |
1987年 | 2篇 |
1986年 | 1篇 |
1984年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有329条查询结果,搜索用时 31 毫秒
1.
Mitsuko Nakashima Hirofumi Kashii Yoshiko Murakami Mitsuhiro Kato Yoshinori Tsurusaki Noriko Miyake Masaya Kubota Taroh Kinoshita Hirotomo Saitsu Naomichi Matsumoto 《Neurogenetics》2014,15(3):193-200
Recessive mutations in genes of the glycosylphosphatidylinositol (GPI)-anchor synthesis pathway have been demonstrated as causative of GPI deficiency disorders associated with intellectual disability, seizures, and diverse congenital anomalies. We performed whole exome sequencing in a patient with progressive encephalopathies and multiple dysmorphism with hypophosphatasia and identified novel compound heterozygous mutations, c.250G>T (p. Glu84*) and c.1342C>T (p. Arg488Trp), in PIGT encoding a subunit of the GPI transamidase complex. The surface expression of GPI-anchored proteins (GPI-APs) on patient granulocytes was lower than that of healthy controls. Transfection of the Arg488Trp mutant PIGT construct, but not the Glu84* mutant, into PIGT-deficient cells partially restored the expression of GPI-APs DAF and CD59. These results indicate that PIGT mutations caused neurological impairment and multiple congenital anomalies in this patient. 相似文献
2.
Tsukasa Ohashi Noriyuki Akasaka Yu Kobayashi Shinichi Magara Hideshi Kawashima Naomichi Matsumoto Hirotomo Saitsu Jun Tohyama 《Epileptic Disord》2014,16(2):208-212
We report a female patient who presented with intractable epileptic seizures, profound developmental delay since early infancy, and hyperkinetic movements with hand stereotypies. The patient initially developed focal seizures with multiple foci at 3 months of age. Thereafter, the seizures evolved to frequent episodes of hyperthermia‐induced status epilepticus. A novel de novo SCN1A mutation was identified by whole‐exome sequence analysis. This case demonstrates that SCN1A mutations may cause movement disorders as an atypical phenotype and the case history of this patient may expand our understanding of the clinical spectrum of SCN1A‐associated epileptic encephalopathy. [Published with video sequences] 相似文献
3.
Different patterns of cerebellar abnormality and hypomyelination between POLR3A and POLR3B mutations
Jun-ichi Takanashi Hitoshi Osaka Hirotomo Saitsu Masayuki Sasaki Harushi Mori Hidehiro Shibayama Manabu Tanaka Yoshiko Nomura Yasuo Terao Ken Inoue Naomichi Matsumoto A. James Barkovich 《Brain & development》2014
Background
Mutations of POLR3A and POLR3B have been reported to cause several allelic hypomyelinating disorders, including hypomyelination with hypogonadotropic hypogonadism and hypodontia (4H syndrome). Patients and methods: To clarify the difference in MRI between the two genotypes, we reviewed MRI in three patients with POLR3B mutations, and three with POLR3A mutations. Results: Though small cerebellar hemispheres and vermis are common MRI findings with both types of mutations, MRI in patients with POLR3B mutations revealed smaller cerebellar structures, especially vermis, than those in POLR3A mutations. MRI also showed milder hypomyelination in patients with POLR3B mutations than those with POLR3A mutations, which might explain milder clinical manifestations. Conclusions: MRI findings are distinct between patients with POLR3A and 3B mutations, and can provide important clues for the diagnosis, as these patients sometimes have no clinical symptoms suggesting 4H syndrome. 相似文献4.
5.
Al-Bajalan Mariwan M. M. Niranji Sherko S. Al-Jaf Sirwan M. A. Kato Hirotomo 《Parasitology research》2018,117(2):585-590
Parasitology Research - Canine leishmaniasis (CanL) caused by Leishmania infantum (L. infantum) is considered as a zoonotic disease and within the last few decades, studies have identified the... 相似文献
6.
Satoshi Akamine Yoshito Ishizaki Yasunari Sakai Hiroyuki Torisu Ryoko Fukai Noriko Miyake Kazuhiro Ohkubo Hiroshi Koga Masafumi Sanefuji Ayumi Sakata Masahiko Kimura Seiji Yamaguchi Osamu Sakamoto Toshiro Hara Hirotomo Saitsu Naomichi Matsumoto Shouichi Ohga 《European journal of medical genetics》2018,61(8):451-454
Mutations in the X-linked gene CDKL5 cause early-onset epileptic encephalopathy and severe developmental delay. Because this disorder predominantly affects females, the full clinical spectrum of male patients remains elusive. We herein report a 16-year-old boy, who suffered from intractable seizures 20 days after birth. Serial electroencephalograms detected recurrent focal epileptiform discharges from age 4 months, which evolved to hypsarrhythmia later in infancy. Mass-spectrometric analyses revealed increase in urinary excretion of methylmalonic acid without perturbed concentrations of propionic acid, homocystein and methionine. Whole-exome sequencing identified a de novo, truncating mutation in CDKL5 (NM_003159.2:c.419dupA, p.Asn140Lysfs*8). Targeted sequencing excluded concomitant mutations in methylmalonic academia-associated genes. No methylmalonic acidemia has been reported in children with CDKL5 disorder. Extensive analyses on organic acid metabolism for males with CDKL5 mutations will gain more insight into their biochemical profiles in infancy. 相似文献
7.
8.
9.
Naoto Shirasu Hiromi Yamada Hirotomo Shibaguchi Motomu Kuroki Masahide Kuroki 《International journal of cancer. Journal international du cancer》2014,135(11):2697-2710
Conventional photodynamic therapy (PDT) for cancer is limited by the insufficient efficacy and specificity of photosensitizers. We herein describe a highly effective and selective tumor‐targeted PDT using a near‐infrared (NIR) photosensitizer, IRDye700DX, conjugated to a human monoclonal antibody (Ab) specific for carcinoembryonic antigen (CEA). The antitumor effects of this Ab‐assisted PDT, called photoimmunotherapy (PIT), were investigated in vitro and in vivo. The Ab‐IRDye conjugate induced potent cytotoxicity against CEA‐positive tumor cells after NIR‐irradiation, whereas CEA‐negative cells were not affected at all, even in the presence of excess photoimmunoconjugate. We found an equivalent phototoxicity and a predominant plasma membrane localization of Ab‐IRDye after both one and six hours of incubation. Either no or little caspase activation and membrane peroxidation were observed in PIT‐treated cells and a panel of scavengers for reactive oxygen species showed only partial inhibition of the phototoxic effect. Strikingly, Ab‐IRDye retained significant phototoxicity even under hypoxia. We established a xenograft model, which allowed us to sensitively investigate the therapeutic efficacy of PIT by non‐invasive bioluminescence imaging. Luciferase‐expressing MKN‐45‐luc human gastric carcinoma cells were subcutaneously implanted into both flanks of nude mice. NIR‐irradiation was performed for only the tumor on one side. In vivo imaging and measurement of the tumor size revealed that a single PIT treatment, with intraperitoneal administration of Ab‐IRDye and subsequent NIR‐irradiation, caused rapid cell death and significant inhibition of tumor growth, but only on the irradiated side. Together, these data suggest that Ab‐IRDye‐mediated PIT has great potential as an anticancer therapeutics targeting CEA‐positive tumors. 相似文献
10.
Koh Y Nakata H Maeda K Ogata H Bilcer G Devasamudram T Kincaid JF Boross P Wang YF Tie Y Volarath P Gaddis L Harrison RW Weber IT Ghosh AK Mitsuya H 《Antimicrobial agents and chemotherapy》2003,47(10):3123-3129
We designed, synthesized, and identified UIC-94017 (TMC114), a novel nonpeptidic human immunodeficiency virus type 1 (HIV-1) protease inhibitor (PI) containing a 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane (bis-THF) and a sulfonamide isostere which is extremely potent against laboratory HIV-1 strains and primary clinical isolates (50% inhibitory concentration [IC(50)], approximately 0.003 micro M; IC(90), approximately 0.009 micro M) with minimal cytotoxicity (50% cytotoxic concentration for CD4(+) MT-2 cells, 74 micro M). UIC-94017 blocked the infectivity and replication of each of HIV-1(NL4-3) variants exposed to and selected for resistance to saquinavir, indinavir, nelfinavir, or ritonavir at concentrations up to 5 micro M (IC(50)s, 0.003 to 0.029 micro M), although it was less active against HIV-1(NL4-3) variants selected for resistance to amprenavir (IC(50), 0.22 micro M). UIC-94017 was also potent against multi-PI-resistant clinical HIV-1 variants isolated from patients who had no response to existing antiviral regimens after having received a variety of antiviral agents. Structural analyses revealed that the close contact of UIC-94017 with the main chains of the protease active-site amino acids (Asp-29 and Asp-30) is important for its potency and wide spectrum of activity against multi-PI-resistant HIV-1 variants. Considering the favorable pharmacokinetics of UIC-94017 when administered with ritonavir, the present data warrant that UIC-94017 be further developed as a potential therapeutic agent for the treatment of primary and multi-PI-resistant HIV-1 infections. 相似文献